Lymphocyte Activation Gene-3 Blocker [EPC]

515 reported adverse events

Drugs of this class: NIVOLUMAB AND RELATLIMAB-RMBW

These side effects are most commonly reported by patients taking drugs of the Lymphocyte Activation Gene-3 Blocker [EPC] class:

# Side effect Count
0 DEATH 76
1 OFF LABEL USE 60
2 MALIGNANT NEOPLASM PROGRESSION 35
3 FATIGUE 19
4 MYOCARDITIS 19
5 PRODUCT STORAGE ERROR 19
6 PRODUCT DOSE OMISSION ISSUE 15
7 ADVERSE EVENT 13
8 COLITIS 13
9 RASH 13
See all common reactions for Lymphocyte Activation Gene-3 Blocker [EPC]

Drugs of the Lymphocyte Activation Gene-3 Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 AUTOIMMUNE ENDOCRINE DISORDER 1 0.0476
1 ASCARIASIS 1 0.0303
2 BRAIN EMPYEMA 1 0.0179
3 IMMUNE-MEDIATED MYASTHENIA GRAVIS 3 0.0092
4 MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME 2 0.0088
5 AUTOIMMUNE LUNG DISEASE 1 0.0085
6 TUMOUR HYPERPROGRESSION 2 0.0081
7 DIABETIC KETOACIDOTIC HYPERGLYCAEMIC COMA 1 0.0055
8 IMMUNE-MEDIATED MYOCARDITIS 6 0.0037
9 BULBAR PALSY 1 0.0036
See all enriched reactions for Lymphocyte Activation Gene-3 Blocker [EPC]